Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

XORTX Therapeutics Inc. (XRTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.3600-0.0500 (-2.07%)
At close: 1:00PM EST
2.3600 0.00 (0.00%)
After hours: 02:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close2.4100
Open2.4000
Bid2.3600 x 1000
Ask2.8000 x 800
Day's Range2.3600 - 2.4350
52 Week Range2.3500 - 5.8900
Volume37,058
Avg. Volume2,092,962
Market Cap30.048M
Beta (5Y Monthly)0.24
PE Ratio (TTM)N/A
EPS (TTM)-0.3250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XRTX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • XORTX Therapeutics Inc.
    XRTX: Lowering target price to $3.00XORTX THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $3.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of Low; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • GlobeNewswire

    XORTX Therapeutics Announces Annual and Special Meeting of Shareholders

    CALGARY, Alberta, Nov. 23, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces that it will hold its annual and special meeting of shareholders at 11:00 a.m. (Calgary time) on Monday, December 20, 2021 (the “Meeting”). Materials for the Meeting have been mailed to shareholders and are available on the Company’s SEDAR

  • PR Newswire

    Argus Research Initiates Equity Research Report Coverage on XORTX Therapeutics Inc. (Nasdaq: XRTX)

    Argus Research, an independent investment research firm, has launched Equity Research Report coverage on XORTX Therapeutics Inc. (Nasdaq: XRTX)

  • GlobeNewswire

    XORTX Therapeutics Announces Partial Exercise of Over-Allotment Option Pursuant to US Public Offering

    CALGARY, Alberta, Nov. 09, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, today announced that it has issued an additional 355,000 common shares at the public offering price of US$4.129 per share, resulting in additional gross proceeds of approximately US$1.47 million pursuant to the partial exercise of the underwriters’ o

Advertisement
Advertisement